Management Team

Nanosphere is led by an experienced management team with an average of over 20 years experience in the development and commercialization of medical diagnostics and devices.

	William Moffitt President and Chief Executive Officer Mr. Moffitt became president and CEO of Nanosphere in 2004. Moffitt is a 30+ year veteran of the diagnostics and medical device industry, having spent the last 20 years developing novel technologies into products and solutions that have helped shape the industry and generate significant shareholder value. Prior to Nanosphere, he served as president and CEO of i-STAT Corporation, a developer, manufacturer and marketer of diagnostic products that pioneered the point-of-care blood analysis market. Moffitt led i-STAT from its early stage to commercialization and from the company's IPO in 1992 to its acquisition by Abbott Laboratories in 2003. Prior to i-STAT, Moffitt held increasingly responsible executive positions from 1973 through 1989 with Baxter Healthcare Corporation, a $7 billion manufacturer and distributor of healthcare products, and American Hospital Supply Corporation, a $3.5 billion diversified manufacturer and distributor of healthcare products, which Baxter acquired in 1985. Moffitt earned a B.S. in zoology from Duke University.
	Michael McGarrity Vice President of Sales and Marketing and Chief Marketing Officer Mr. McGarrity, who has more than 17 years of sales and marketing experience in the medical device industry, joined Nanosphere after 13 years with Stryker Corporation. He served in leadership roles in marketing and strategic development, most recently as vice president of marketing for Stryker Instruments, a $700 million division of the $4.3 billion Stryker Corporation. In this position, McGarrity's marketing and business development acumen guided the company into markets such as post-operative pain management, waste management and interventional pain management which now account for more than 20 percent of the division's revenue. He also had executive general management responsibility for a newly created business focused on interventional pain management. McGarrity is a graduate of the University of Notre Dame and began his career in commercial banking in Chicago.
	Roger Moody Vice President of Finance, Treasurer and Chief Financial Officer Roger Moody has more than 17 years of experience in leading finance, corporate development and operations for high growth healthcare and technology companies. Previously, Mr. Moody spent six years as COO and CFO at Medsn, a medical education company, where he led the company’s growth from a development stage venture to a global leader in scientific communications. Mr. Moody also served as CFO and led corporate development for two venture backed companies sold to strategic partners. Additionally, Mr. Moody provided M&A and strategic advisory services to technology and healthcare companies for Volpe Brown Whelan & Company. Mr. Moody began his career at IBM where he contributed to the rapid growth of IBM Global Services. Mr. Moody received his BS from Syracuse University and his MBA from the University of Chicago, Graduate School of Business.
	Greg Shipp, M.D. Chief Medical Officer Dr. Shipp joined Nanosphere in 2005 as the company's first vice president of medical affairs. He was previously medical director and chief medical executive at i-STAT Corporation, an Abbott Point-of-Care business. At i-STAT, Shipp was charged with developing a strong working relationships with the medical and clinical laboratory communities and the company's customer base, including physicians and laboratorians worldwide. Prior to i-STAT, he was director of clinical affairs for Boston Scientific Medi-tech, where he managed the process of obtaining FDA and ethical committee approvals to begin clinical evaluation of a stent-graft for endovascular exclusion of infra-renal abdominal aortic aneurysms. Shipp was senior medical officer at Bio-Reg Associates, where he led clinical studies of Class III medical devices in the areas of ophthalmology, plastic surgery, urology and bone physiology. He holds an M.D. from the University of North Carolina School of Medicine and M.S. and B.S. degrees in biomedical engineering from Northwestern University.
	Bill Athenson Vice President of International Sales and Marketing Mr. Athenson brings to Nanosphere more than 21 years of healthcare experience in clinical diagnostics, medical devices and information technology with Fortune 500 companies such as Baxter, American Scientific Products, Allegiance Healthcare and two start-up technology companies. Before joining Nanosphere in January 2002, Mr. Athenson served as General Manager for Allegiance Healthcare with P&L responsibility for a $120 million revenue base. At Allegiance and in previous leadership positions at Baxter Diagnostics and American Scientific Products, he maintained a consistent track record for leading business development, consulting, and operations teams which consistently achieved double-digit revenue and EBITDA growth in the clinical-laboratory and point-of-care markets. Most recently he headed business development teams in two new technology start-up companies achieving successful launches. Mr. Athenson holds an M.B.A. from Kellogg School of Business and a bachelor's degree from Fordham University.
	Winton Gibbons Senior Vice President of Business Development Winton G. Gibbons joined Nanosphere midyear 2007 as Senior Vice President of Business Development. From 2005 to 2007, he was Senior Vice President for Strategic and Global Product Marketing at Biosite (now Inverness Medical). For the period of 1997 through 2005, he was a sell-side equity analyst for the investment firm of William Blair & Company, L.L.C., covering diagnostic, life science and biotech biotechnology companies, and during which he became a Principal, as well as Group Head for healthcare. Prior to that position, from 1994 to 1997, Mr. Gibbons was Vice President of Strategy and Business Development for the Patient Care Division of Boehringer Mannheim Diagnostics (now Roche Diagnostics). He has also been a Director of Management Services at Merck & Co., a consultant and manager at McKinsey & Company, and held marketing and sales positions at Conoco Chemicals, where he began his career. Mr. Gibbons holds an M.B.A. in Finance and Business Policy from the University of Chicago—Graduate School of Business and a Bachelor of Science degree in Chemistry from Duke University.
	Thomas F. Holzman, Ph.D. Vice President of Research, Protein Sciences Dr. Holzman has detailed experience in performing, directing and managing all phases of protein science research for the creation and preparation of pharmaceutically relevant protein targets, antigens, hybridoma-derived and transient monoclonal antibodies (surrogate biologics, produced at gram-scale) for biological and physical (mechanistic) characterization, intellectual property development and surrogate animal model studies. His skills include multi-project management, group leadership, including employee development and motivation. He has developed and staffed core research and support functions for molecular biology, fermentation biochemical engineering, cell biology, protein biochemistry/biophysics and related research areas. His research activities have supported small-molecule drug discovery for therapeutic project team biological efforts, structure-based drug design (protein crystallography and NMR), high-throughput screening as well as biologic therapeutic agent R&D. In supporting these R&D activities he has led development and implementation of customized, enterprise-wide (web-based), informatics systems for integrating protein science laboratory research and work-flows with world-wide project teams of scientists. He started his career at The Upjohn Company as a research physical biochemist. Since joining Abbott Laboratories in 1988 he served as both a Volwiler Research Fellow and Project Leader for Protein Biochemistry in the Advanced Technology area of Global Pharmaceutical R&D. Over 22 years in these positions he has worked on and managed the cloning, expression, fermentation, isolation and biochemical/biophysical characterization of thousands of proteins as rare reagents to effectively ensure that critical biophysical qualities and properties achieve research needs. His projects have spanned the range from growth hormone therapeutics, small-molecule therapeutic targets such as HIV proteinase to aid novel potent inhibitors of AIDS virus replication, and monoclonal antibody expression, purification and characterization supporting on-market and in-development therapeutic biologics. Dr. Holzman was an Upjohn post-doctoral fellow in the Department of Biochemistry and Biophysics at Texas A&M in College Station, Texas (1981-1983). He received his Ph.D. in Biochemistry at the University of Illinois in Urbana in 1982.
	Greg Pletta, J.D. LL.M Vice President of Intellectual Property Gregory T. Pletta brings a wealth of legal experience in the biotechnology field to his position as Nanosphere's Vice President, Intellectual Property. Mr. Pletta will lead the assessment, patenting, and licensing of the proprietary knowledge produced by Nanosphere's scientific and technical staff. Previously, Mr. Pletta was Corporate Counsel at EraGen Biosciences, Inc. Prior to that, he served as Patent Counsel & Intellectual Property Manager at Epicentre Biotechnologies. Before Epicentre, Mr. Pletta was in-house counsel at Promega Corporation focusing on patent litigation and intellectual property matters. Mr. Pletta earned a master's law degree in Intellectual Property from the John Marshall Law School, a degree in law from Capital University, and a Bachelor of Science degree in Genetics from the University of Wisconsin-Madison. While at UW-Madison, he performed autoradiography, chromatography, electrophoresis, nucleic acid isolation, and/or protein purification related to the biochemistry of 2'5' oligoadenylate and its role in the mechanism of action of interferon and the study of antibiotics as regulators of gene expression. Technical assistance is recognized in the Journal of Biological Chemistry, vol. 262:17683-17689 (1987). He is currently licensed to practice law in Illinois and Wisconsin, the U.S. District Courts for the Northern District of Illinois and the Western District of Wisconsin, the U.S. Court of Appeals for the Federal Circuit, and registered to practice before the U.S. Patent & Trademark Office.